Leerink Partners - Latest News and Information
Technology Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Leerink Partners is a healthcare-focused investment bank specializing in advising innovation-driven and growth-minded healthcare companies. The firm offers services across investment banking, capital markets, and institutional equities, with emphasis on biopharma, digital health and health tech, healthcare services, and medical technology sectors. Based in the United States with international expansion, Leerink positions itself as a partner to healthcare companies and their investors. The firm highlights decades of experience and a deep industry network to support transactions and strategic financings.
5 FDA Decisions to Watch in the First Quarter of 2026
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
3 Trends Shaping the GLP-1 Landscape
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
Alumis Soars as TYK2 Drug Hits Mark in Psoriasis Trials
Qiagen N.V. (QGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
J&J Eyes $100B in Sales Amid Gains for Cancer, Immune Drugs
Amgen Gives up on Its Once-Prized Eczema Drug
William Blair Reiterates Outperform on ARS Pharma Stock After FDA Label Update
BioNTech Cofounders To Step Down. Stock Crumbles.
Big Pharma Tight-Lipped on Details of API Stockpile Deals
No recent deals for this company.
